Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer
Background. An elevated platelet count is often associated with malignancies, and it has been confirmed as an adverse prognostic factor in various cancers including early stage breast cancer. We sought to determine if thrombocytosis is also a prognostic factor in metastatic breast cancer. Patients a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2013/289563 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556740824006656 |
|---|---|
| author | Athina Stravodimou Ioannis A. Voutsadakis |
| author_facet | Athina Stravodimou Ioannis A. Voutsadakis |
| author_sort | Athina Stravodimou |
| collection | DOAJ |
| description | Background. An elevated platelet count is often associated with malignancies, and it has been confirmed as an adverse prognostic factor in various cancers including early stage breast cancer. We sought to determine if thrombocytosis is also a prognostic factor in metastatic breast cancer. Patients and Methods. The records of 165 metastatic breast cancer patients with complete follow-up that had thrombocytosis or normal platelet counts were reviewed. Kaplan-Meier curves were constructed, and the survivals of the two groups were compared using the LogRank test. A Cox regression analysis was used to determine if thrombocytosis is an independent factor for overall and progression free survival. Results. There was a statistically significant difference in overall and progression free survival favoring the normal platelets group (LogRank test and 0.008, resp.). Thrombocytosis remained a significant adverse prognostic factor in multivariate analysis. Other independent prognostic factors for overall survival included age, ER/PR status, and grade. Conclusion. Thrombocytosis represents an independent adverse prognostic factor in patients with metastatic breast cancer. Thus metastatic breast cancer joins a range of cancers in which this easily measurable value can be used for clinical prognostication. Further use as a predictive value for specific treatments has a rationale and deserves to be investigated. |
| format | Article |
| id | doaj-art-49d5be9d90394e71bf321f53235159ce |
| institution | Kabale University |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-49d5be9d90394e71bf321f53235159ce2025-02-03T05:44:24ZengWileyInternational Journal of Breast Cancer2090-31702090-31892013-01-01201310.1155/2013/289563289563Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast CancerAthina Stravodimou0Ioannis A. Voutsadakis1Department of Medical Oncology, University Hospital of Lausanne, 1011 Lausanne, SwitzerlandDepartment of Medical Oncology, University Hospital of Lausanne, 1011 Lausanne, SwitzerlandBackground. An elevated platelet count is often associated with malignancies, and it has been confirmed as an adverse prognostic factor in various cancers including early stage breast cancer. We sought to determine if thrombocytosis is also a prognostic factor in metastatic breast cancer. Patients and Methods. The records of 165 metastatic breast cancer patients with complete follow-up that had thrombocytosis or normal platelet counts were reviewed. Kaplan-Meier curves were constructed, and the survivals of the two groups were compared using the LogRank test. A Cox regression analysis was used to determine if thrombocytosis is an independent factor for overall and progression free survival. Results. There was a statistically significant difference in overall and progression free survival favoring the normal platelets group (LogRank test and 0.008, resp.). Thrombocytosis remained a significant adverse prognostic factor in multivariate analysis. Other independent prognostic factors for overall survival included age, ER/PR status, and grade. Conclusion. Thrombocytosis represents an independent adverse prognostic factor in patients with metastatic breast cancer. Thus metastatic breast cancer joins a range of cancers in which this easily measurable value can be used for clinical prognostication. Further use as a predictive value for specific treatments has a rationale and deserves to be investigated.http://dx.doi.org/10.1155/2013/289563 |
| spellingShingle | Athina Stravodimou Ioannis A. Voutsadakis Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer International Journal of Breast Cancer |
| title | Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer |
| title_full | Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer |
| title_fullStr | Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer |
| title_full_unstemmed | Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer |
| title_short | Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer |
| title_sort | pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer |
| url | http://dx.doi.org/10.1155/2013/289563 |
| work_keys_str_mv | AT athinastravodimou pretreatmentthrombocytosisasaprognosticfactorinmetastaticbreastcancer AT ioannisavoutsadakis pretreatmentthrombocytosisasaprognosticfactorinmetastaticbreastcancer |